This strategic move is a result of the initiatives led by Ravi Achar, Chief Business Officer at Afecta Pharmaceuticals and Brent A. Reinke, Founder and Chairman of The BioScience Alliance (BSA). The focus is on bringing biotechnology partnership opportunities to India. Mr. Reinke is a partner in the Corporate and Securities practice group at Stradling Yocca Carlson & Rauth, Southern California’s 101 Corridor’s premier business law firm.
Afecta’s vision is to lead in the growing need for more ethical and efficient drug testing methods as the industry shifts towards alternative technologies in compliance with regulatory advancements such as the FDA Modernization Act 2.0. The DART platform aligns with Afecta’s PharmetRx-AI platform for new drug discovery and development. The DART platform enables the Transcell Biologics animal-free testing strategy. Transcell’s models are instrumental in assessing the safety and efficacy issues of drug candidates and facilitating first-in-human trials. DART integrates well with existing PharmetRx workflows for an industrialized approach to drug discovery and development.
Bruce Kovacs, MD, Founder and CEO of Afecta Pharmaceuticals, noted “…integrating DART into our workflows is a transformative step that underscores our unwavering commitment to creating innovative therapies that elevate patient outcomes. Afecta is committed to reducing the need for animal toxicity testing in our development programs and Transcell’s platforms will be a great resource to that end”.
Subhadra Dravida, PhD, Founder and CEO of Transcell Biologics, remarked, “We are pleased to work with Afecta’s team to strengthen their ongoing drug development initiatives. This engagement is expected to continuously deliver critical, clinical surrogate insights that complement the existing data on Afecta’s assets.”
Uday Chatterjee, a Director of Transcell Biologics and a member of Afecta Pharmaceuticals Advisory Board, highlighted that “…this partnership can lower the costs of clinical drug development and bring investigational drug candidates to the market more rapidly”.
Afecta Pharmaceuticals is a clinical-stage small molecule therapeutics company. Afecta leverages its core technologies for AI-driven drug discovery and nano-material formulation to be more efficient in the process of discovery and development of precision medicines. The company has a pipeline of multi-target, de-risked drug candidates to treat complex diseases more effectively than traditional single-target drugs.
Transcell Biologics is company that translates adult stem cell technology into real-world applications. They have developed an industrialized animal-free testing strategy designated “DART” that utilizes human iPSC cellular models and advanced artificial intelligence for in-vitro drug testing. This breakthrough approach provides pre-clinical testing solutions with direct clinical relevance to the industry.
–END–